Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment
Metrics: PDF 2332 views | HTML 2025 views | ?
Bin Zhang1,2,*, Yuhao Dong1,2,*, Jing Liu1,2, Zhouyang Lian1,2, Long Liang1,2, Wenbo Chen3, Xiaoning Luo1,2, Shufang Pei1,2, Xiaokai Mo1,2, Lu Zhang1,2, Wenhui Huang1,4, Fusheng Ouyang1,2, Baoliang Guo1,2, Changhong Liang1 and Shuixing Zhang1
1 Department of Radiology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, P.R. China
2 Graduate College, Southern Medical University, Guangzhou, Guangdong, P.R. China
3 Department of Radiology, Huizhou Municipal Central Hospital, Huizhou, Guangdong, P.R. China
4 School of medicine, South China University of Technology, Guangzhou, Guangdong, P.R. China
* These authors have contributed equally to this work
Shuixing Zhang, email:
Keywords: immunotherapy; chemotherapy; advanced pancreatic cancer; adverse events; overall survival
Received: July 15, 2016 Accepted: December 12, 2016 Published: December 15, 2016
There are limited data on the safety and efficacy of immunotherapy for patients with advanced pancreatic cancer (APC). A meta-analysis of single-arm trials is proposed to assess the efficacy and safety of immunotherapy for APC. Eighteen relevant studies involving 527 patients were identified. The pooled disease control rate (DCR), overall survival (OS), progression free survival (PFS), and 1-year survival rate were estimated as 59.32%, 7.90 months, 4.25 months, and 30.12%, respectively. Subgroup analysis showed that the pooled OS, PFS, and 1-year survival rate were significantly higher for autologous activated lymphocyte therapy compared with peptide-based vaccine therapy (OS: 8.28 months vs. 7.40 months; PFS: 6.04 months vs. 3.86 months; 1-year survival rate: 37.17% vs. 19.74%). Another subgroup analysis demonstrated that the pooled endpoints were estimated as obviously higher for immunotherapy plus chemotherapy compared with immunotherapy alone (DCR: 62.51% vs. 47.63%; OS: 8.67 months vs. 4.91 months; PFS: 4.91 months vs. 3.34 months; 1-year survival rate: 32.32% vs. 21.43%). Of the included trials, seven trials reported no treatment related adverse events , five trials reported (16.6 ± 3.9) % grade 3 adverse events and no grade 4 adverse events. In conclusion, immunotherapy is safe and effective in the treatment of APC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.